Physician profile
Vikram Jala
NPI 1104279595
$2,368.24
in general payments reported to CMS, 2019-2025
22 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $266 · 2021: $79.66 · 2022: $573 · 2023: $104 · 2024: $208 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $483.82 | 2022 | |
| Abbvie INC. | $368.67 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.40 | 2019-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $221.79 | 2019 | |
| Janssen Biotech, INC. | $177.86 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $161.46 | 2019-2020 | |
| Amgen INC. | $110.44 | 2023-2024 | Tezspire |
| Dova Pharmaceuticals | $105.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.02 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.09 | 2023-2025 | Dupixent |
| Philips North America LLC | $33.04 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Shionogi INC | $29.87 | 2024 | Fetroja |
| Pfizer INC. | $27.38 | 2020 | |
| Zoll Respicardia, INC. | $26.02 | 2025 | Remede System |
| Nabriva Therapeutics, Plc | $25.30 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.17 | 2025 | |
| Intercept Pharmaceuticals, INC. | $18.66 | 2019 | |
| Kaleo, INC. | $17.66 | 2024 | Auvi-Q |
| Redhill Biopharma INC. | $15.66 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $14.68 | 2025 | Neffy |
| Capsovision, INC. | $14.62 | 2025 | Capsocam Plus |
| Allergan, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Jala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.